44 results about "Micronazole" patented technology

The invention discloses an Acinetobacter ZJPH1806 and its application in the preparation of a chiral intermediate of miconazole. (R)-2-chloro-1 is prepared by asymmetric reduction of 2,2',4'-trichloroacetophenone ‑(2,4‑chlorophenyl)ethanol, the product obtained is of high optical purity. In the pH 7.6 phosphate buffer system, with glycerol as the auxiliary substrate, 2g / L substrate was added to react for 26h, the yield of R-type product was 83.2%, and the e.e. value was >99.9%.

The present disclosure relates to an improved method for producing ergothioneine, comprising the steps of: (a) inoculating Pleurotus ostreatus strain CGMCC No.6232 into a seed medium, and culturing it to prepare a seed liquor, wherein the seed medium uses soybean cake powder as nitrogen source; and (b) inoculating the seed liquor into a fermentation basal medium, and then culturing it to obtain a fermentation broth of Pleurotus ostreatus mycelia. Further, any one or more members selected from NH4Cl, NH4NO3, NaCl, polyethylene glycol, folic acid, vitamin B1 (VB1), indolebutyric acid, citric acid, pyruvic acid, arginine, lysine, leucine, aspartic acid, glutamic acid, betaine, histidine, cysteine, methionine, tween, span, chitosan, Fluconazole, Miconazole, Ketoconazole, ethylenediaminetetraacetic acid (EDTA), isopropyl alcohol and dimethyl sulfoxide are added into the fermentation basal medium.

Methods of treating infections caused by free-living amoeba are disclosed. The methods generally include systemic administration of an effective amount of miltefosine, such as an oral or intravenous formulation, and optionally local administration of an effective amount of miltefosine, such as a topical formulation of miltefosine. The methods may further include administration of one or more secondary agents. Exemplary secondary agents include steroids, polyhexamethylene biguanide (PHMB), chlorhexidine, propamidine isethionate, dibromopropamidine isethionate, neomycin, paromomycin, polymyxin B, clotrimazole, ketoconazole, miconazole, and itraconazole. The methods may be used to treat patients with infections caused by a free-living amoeba such as Naegleria fowleri, Balamuthia mandrillaris, Sappinia diploidea, and Acanthamoeba species. Exemplary infections include Acanthamoeba keratitis, granulomatous amoebic encephalitis, cutaneous acanthamoebiasis, primary amoebic meningoencephalitis, Sappinia amoebic encephalitis, or a disseminated disease associated with a free-living amoeba.

The invention belongs to the technical field of medicine, and relates to the new application of miconazole and derivatives thereof in treating diseases and diseases of biopathological processes in which TGR5 participates. The structural formulas of the miconazole and its derivatives are as follows. The miconazole and its analogues can activate TGR5 activity, and can be used for treating or preventing diseases related to the regulation of TGR5 activity.

The invention discloses a dermatophytosis preparation. In the dermatophytosis preparation, miconazole nitrate and triclosan are main bactericidal components and can generate a synergistic effect by matched use to enhance a bactericidal effect; urotropin mainly plays roles in convergence and hidroschesis in a formula and simultaneously has a bactericidal effect; hexadecadrol is a corticosteroid drug and mainly plays anti-inflammatory and anti-pruritic roles in the formula; dimethyl sulfoxide mainly plays a solubilizing role in the formula to dissolve the miconazole nitrate and the hexadecadroland simultaneously has a trans-dermal effect to enhance the trans-dermal absorption of the drug and enhance the drug effect; laurocapram is a trans-dermal absorbing agent to enhance the drug trans-dermal absorption function; glycerol is a moisturizing agent and mainly plays roles in moisturizing skin, reducing irritation and increasing drug adhesion in the formula; medical ethanol is mainly used as a solvent and simultaneously has a bactericidal effect; menthol and essence are taken as flavoring agents to improve the drug odor and improve the use experience; the dermatophytosis preparation simultaneously has the effect of covering the foot odor.

Antimicrobial and contraceptive compositions and methods which prevent and / or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and / or reduce the risk of pregnancy are provided. The compositions contain (1) a matrix-forming agent, (2) a bio-adhesive agent, (3) a buffering agent, (4) optionally a humectant, (5) optionally a preservative, and (6) water; wherein the composition is suitable for application within the vagina; wherein the compositions forms a semisolid matrix on contact with ejaculate (thereby trapping ejaculated microbes and spermatozoa); wherein the composition causes hardening of cervical mucus (thereby decreasing the probability of sperm entry); wherein the composition forms a bio-adhesive layer over vaginal surfaces (thereby preventing or reducing the risk of contact of STD-causing microbes with the vaginal surfaces); wherein the composition maintains an acidic vaginal pH of less than about 5 in the presence of semen ejaculated from the male; and wherein the composition does not significantly impair the natural microbiological balance within the vagina. The antimicrobial and contraceptive compositions may also contain additional antimicrobial and / or contraceptive agents (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2SO4-modified mandelic acids, povidone iodine, itraconazole, ketoconazole, metronidazole, clotrimazole, fluconazole, teraconazole, miconazole, tinidazole, iconazole, chloramphenicol, nystatin, cyclopiroxolamine, and the like).